We raised 240 MM JPY during a second round of financing from Anniversaire Holdings Inc., Beyond Next Ventures Inc., Miyagin Venture Capital Inc., and SMBC Venture Capital Inc.
Second Financing Round Completed for 240 MM JPY
MabGenesis Inc. (Headquarters: 3 Chome-7-18 Shinyokohama, Kohoku Ward, Yokohama, Kanagawa, CEO: Shinjo Katsuhiro) has completed a second round of financing for a total of 240 MM JPY form Anniversaire Holings Inc. (Headquarters: Minato, Tokyo; CEO: Masamitsu Aoki), Beyond Next Ventures Inc. (Headquarters: Chuo, Tokyo; CEO: Tsuyoshi Ito), Miyagin Venture Capital Inc. (Headquarters: Miyazaki City, Miyazaki), and SMBC Venture Capital Inc. (Headquarters: Chuo, Tokyo; CEO: Koichi Noda).
Funding Underwriters (Operational Management)
- Anniversaire Holdings Inc.
- Nagoya University/Tokai University Area Venture No. 2 Investment Business Association(Beyond Next Ventures Inc.)
- Miyagin Miyazaki University Dream Support Investment Business Limited Liability Partnership(Miyagin Venture Capital Inc.)
- SMBC Venture Capital Industry-Academia Collaboration No. 2 Investment Business Limited Liability Partnership(SMBC Venture Capital Inc.)
A startup biopharmaceutical company from Miyazaki University and Fujita Medical University. Through the creation (Genesis) of innovative monoclonal antibodies (Mab), we seek to improve the health and lives of people and animals. By utilizing many years of academic research, we have succeeded in dramatically improving antibody diversity and functionality, which were the weaknesses of the phage display antibody library technology. We have established a technology to rapidly obtain new monoclonal antibodies (first-in-class) against low antigenic substances such as membrane complexes, which have been difficult to obtain until now, as well as new monoclonal antibodies with superior properties to existing antibodies (best-in-class).
Press Release (Japanese)